Zogenix, Inc. Announces FDA Approval Of 4 Mg SUMAVEL® Dosepro® (Sumatriptan Injection) Needle-Free Delivery System

Published: Dec 10, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO, Dec. 10, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders and pain, announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for a 4 mg dose of SUMAVEL DosePro (sumatriptan injection) Needle-free Delivery System. SUMAVEL DosePro has been available in a 6 mg dose for the treatment of acute migraine and cluster headache. The 4 mg dose of SUMAVEL DosePro can be used to help migraine sufferers who require management of side effects. The 4 mg dose of SUMAVEL DosePro is expected to be available approximately June 2014.

Help employers find you! Check out all the jobs and post your resume.

Back to news